PURPOSE CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that in first-line
patients with metastatic colorectal cancer (mCRC) treated with bevacizumab or cetuximab …

PURPOSE CALGB/SWOG 80405 was a randomized phase III trial that found no statistically
significant difference in overall survival (OS) in patients with first-line metastatic colorectal …

3504 Background: CALGB 80405 was a randomized phase III trial that found no difference
in OS in first-line mCRC pts treated with either bevacizumab (Bev) or cetuximab (Cet) …

Anti-BRAF/EGFR therapy is approved for metastatic colorectal cancer (mCRC) with BRAF
V600E mutations, although not all patients respond. Novel recent findings indicate the …

Abstract Background CALGB (Alliance)/SWOG 80405 was a randomized phase III trial that
found no difference in overall survival (OS) in first-line mCRC Patients (pts) treated with …

BRAF mutations are found in up to 10% of colorectal cancers (CRC). Whereas the majority
of BRAF mutant CRCs harbor V600 mutations, up to 25% express non-V600 BRAF …

Background: Colorectal cancer (CRC) has been reconsidered as a heterogeneous disease.
Among advances of genomic analysis in CRC, the sidedness of tumors (left-sided colon vs …

BACKGROUND Early identification of mutations may guide patients with metastatic
colorectal cancer toward targeted therapies that may be life prolonging. The authors …

The BRAF-V600E mutation is associated with poor prognosis and limited response to
standard therapies. The BEACON trial demonstrated the benefits of a BRAF inhibitor …

3528 Background: BRAF V600 mutations occur in 10-15% of CRC and may predict lack of
response to standard chemotherapy and anti-EGFR treatment. There have been no …